Key insight: Several biotech firms, including BrainStorm, AB Science, and Neuraltus, are forging ahead with drugs to treat aspects of ALS. Scientists are hopeful — but cautious.

C

onsidering it took more than two decades for a second ALS drug to make it to the US market, you might think that few companies are willing to take the risk of developing such treatments.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

    • Out of 60 ALS patients only one had Borrelia but they also had ALS. All had gut yeast infections, 58 had heavy metal toxicity and most had improvements with stem cells. A major problem is cervical osteoarthritis with osteophytes of long duration that when re-injured allows toxins to move from the gut into the CSF

  • The cause of ALS and many other ND is a Borrelia infection. We are wasting Billions of dollars on wrong research.

    • I have ALS and I was told there is nothing that can be done and they just gave me 2 years to live.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X